Australian Pharmaceutical Industries Ltd (ASX: API) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Australian Pharmaceutical Industries Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $721.74 million
P/E Ratio 10.05
Dividend Yield 2.76%
Shares Outstanding 492.66 million
Earnings per share -0.029
Dividend per share 0.04
Year To Date Return 4.47%
Earnings Yield 9.95%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Australian Pharmaceutical Industries Ltd (ASX: API)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
06 May 2021 $0.0150 100.00% Interim 04 Jun 2021
11 Nov 2020 $0.0200 100.00% Final 15 Dec 2020
13 Nov 2019 $0.0400 100.00% Final 12 Dec 2019
02 May 2019 $0.0375 100.00% Interim 31 May 2019
08 Nov 2018 $0.0400 100.00% Final 07 Dec 2018
03 May 2018 $0.0350 100.00% Interim 01 Jun 2018
09 Nov 2017 $0.0350 100.00% Final 08 Dec 2017
04 May 2017 $0.0350 100.00% Interim 02 Jun 2017
03 Nov 2016 $0.0350 100.00% Final 09 Dec 2016
05 May 2016 $0.0250 100.00% Interim 03 Jun 2016
04 Nov 2015 $0.0250 100.00% 04 Dec 2015
06 May 2015 $0.0200 100.00% 05 Jun 2015
12 Nov 2014 $0.0200 100.00% 12 Dec 2014
07 May 2014 $0.0150 100.00% 06 Jun 2014
11 Nov 2011 $0.0150 0.00% Final 15 Dec 2011

API ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Australian Pharmaceutical Industries Ltd

Australian Pharmaceutical Industries Ltd (ASX: API) is an Australian company with three key areas of operation: retail, wholesale distribution and business advisory. The company is probably best known for its retail pharmacy and health and beauty brands, Soul Pattinson and Priceline.

Priceline was acquired by API in 2004 and has more than 420 stores Australia-wide. Priceline stores are wholly owned by API whereas Priceline Pharmacies are operated under a franchise model.

In addition to its pharmacy brands, API owns a chain of 57 cosmetic, skin and laser hair removal clinics in Australia and New Zealand called Clear Skincare Clinics. It also produces a range of products under the Clear Skincare brand which it sells through Priceline Pharmacy.

API’s operations include retail services which encompass marketing programs and business advice.

API was established in 1910 and listed on the ASX in 1997. The API share price was hit hard by the February/March 2020 bear market, falling as low as $1 on 23 March. Since then, as at October 2020, the API share price has continued trading at between $1 and $1.20.

API Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 Sep 2021 $1.48 $0.21 16.54% 5,594,070 $1.46 $1.49 $1.44
15 Sep 2021 $1.27 $-0.01 -0.78% 735,329 $1.30 $1.30 $1.26
14 Sep 2021 $1.28 $-0.04 -3.02% 1,442,992 $1.33 $1.34 $1.28
13 Sep 2021 $1.33 $0.00 0.00% 539,784 $1.33 $1.33 $1.31
10 Sep 2021 $1.33 $-0.01 -0.75% 755,218 $1.33 $1.33 $1.31
09 Sep 2021 $1.33 $-0.03 -2.20% 688,138 $1.37 $1.37 $1.32
08 Sep 2021 $1.37 $0.03 2.25% 1,001,488 $1.35 $1.37 $1.33
07 Sep 2021 $1.34 $-0.02 -1.48% 668,797 $1.35 $1.36 $1.33
06 Sep 2021 $1.35 $0.01 0.74% 949,571 $1.36 $1.36 $1.32
03 Sep 2021 $1.35 $-0.01 -0.74% 650,403 $1.36 $1.36 $1.33
02 Sep 2021 $1.36 $0.02 1.50% 741,921 $1.34 $1.36 $1.34
01 Sep 2021 $1.33 $-0.01 -0.74% 506,157 $1.33 $1.35 $1.32
31 Aug 2021 $1.35 $0.02 1.51% 1,347,200 $1.30 $1.35 $1.30
30 Aug 2021 $1.33 $-0.02 -1.49% 1,328,793 $1.36 $1.38 $1.30
27 Aug 2021 $1.35 $-0.04 -2.88% 1,142,821 $1.39 $1.39 $1.34
26 Aug 2021 $1.39 $0.04 2.97% 821,168 $1.35 $1.40 $1.35
25 Aug 2021 $1.35 $-0.05 -3.57% 1,870,411 $1.39 $1.39 $1.34
24 Aug 2021 $1.40 $0.00 0.00% 441,475 $1.40 $1.41 $1.39
23 Aug 2021 $1.40 $0.00 0.00% 1,294,802 $1.40 $1.41 $1.40
20 Aug 2021 $1.40 $0.01 0.72% 1,375,000 $1.39 $1.41 $1.39
19 Aug 2021 $1.39 $-0.02 -1.42% 832,580 $1.41 $1.41 $1.39
18 Aug 2021 $1.41 $0.00 0.00% 765,027 $1.40 $1.42 $1.40

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Feb 2021 Richard Vincent Issued 825 $1,056,512
Issue of securities. 1,738,065 - performance rights
14 Dec 2020 Jennifer (Jenny) Macdonald Buy 25 $32,625
On-market trade.
16 Nov 2020 Richard Vincent Expiry 402 $440,479
As advised by the company. 912,665 - performance rights
Lapsing of performance rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Richard Craig Vincent Chief Executive OfficerManaging Director Feb 2017
Mr Vincent started his professional career in finance with Bridgestone before moving to Britax Rainsfords where he was CFO. He served at FH Faulding & Co Limited in 1998 and remained with that company until 2005, during which time he held a number of senior leadership roles, including responsibility for the pharmacy distribution, retail merchandise and generic pharmaceutical development. He has held a number of general management roles including pharmacy distribution and business development, strategy, supply chain, franchise recruitment, IT, manufacturing and mergers and acquisitions. Mr Vincent is the Chair of the National Pharmaceutical Services Association and was also a Director of CH2 Holdings Pty Ltd from 2006 to 2015.
Mr Kenneth William Gunderson-Briggs Non-Executive DirectorNon-Executive Chairman May 2014
Mr Gunderson-Briggs is a public company director with experience in the finance and retail franchise sectors. He was a Director of Glenaeon Rudolf Steiner School Limited from 2009 and its Chair from 2013 until 2018. Mr Gunderson-Briggs has been an Independent Non-executive Director of Harvey Norman Holdings Limited since June 2003. He is also Chair of Risk Committee of the Company
Ms Lee Ausburn Non-Executive Director Oct 2008
Ms Ausburn has experience in retail and hospital pharmacy and in academia. She had a career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President, Asia, for Merck and Co Inc with responsibility for the company's operations across Asia. Ms Ausburn was President, Pharmacy Faculty Foundation, University of Sydney until December 2017. She is a Director of nib Holdings Limited (Since November 2013) and was a former director of SomnoMed Limited (September 2011 - 24 August 2020). She is a member of the Risk Committee.
Ms Jennifer (Jenny) Mitchell Macdonald Non-Executive Director Nov 2017
Ms Macdonald has a background in financial and general management roles across a range of industry sectors including fast moving consumer goods, travel and digital media. Ms Macdonald was previously Chief Financial Officer and Interim Chief Executive Officer at Helloworld Travel and Chief Financial Officer and General Manager International at REA Group. She is a Director of Redbubble Limited (Since February 2018) and Bapcor Limited (Since September 2018) She was a former Director of Redflow Limited (December 2017 - September 2019). She is a member of the Risk Committee.
Ms Janine Suzanne Allis Non-Executive Director Oct 2020
Ms Allis has retail and franchising experience, having founded Boost Juice Bars and grown three other food retail brands within the Retail Zoo group. Ms Allis has won many retail and franchise awards, including the Excellence in International Franchising and Franchise Innovation awards from the Franchise Council of Australia and the Telstra Businesswoman of the Year award. Ms Allis is a non-executive director of the Olivia Newton-John Foundation and an Ambassador for the United Nations High Commission for Refugees in Australia: Australia for UNHCR. She has been a non-executive director of Michael Hill International (ASX:MHJ) for the last four years and will step down on 27 October 2020.
Mr Clive Stiff Non-Executive Director Dec 2020
Mr Stiff has served as Chief Executive Officer of Unilever Australia and New Zealand from April 2012 to March 2020. Prior to that, he held senior leadership roles at Goodman Fielder and Procter & Gamble. Mr Stiff is currently an external advisor to Bain & Company and a member of the Advisory Board of Quantium, one of the data science and artificial intelligence companies. Mr Stiff was formerly the Chair of the Australian Food & Grocery Council, the Chair of T2 Tea and a Non-executive Director of Foodbank NSW & ACT. Clive has a 34-year of career in leading global FMCG businesses.
Mr George Tambassis Non-Executive Director Jun 2021
Mr Tambassis has a knowledge of the pharmacy sector, with strategic and operational experience developed over 35 years, including 15 years as a director of the Pharmacy Guild of Australia. During seven and a half years as the Guild's National President, he headed negotiations between the Government and the Guild to conclude the 6th and 7th Community Pharmacy Agreements. Mr Tambassis has operated community pharmacies for more than 30 years. He was also inaugural President of the World Pharmacy Council and an Associate Expert Group member at the OECD advising on global best practice approaches and innovations in pharmacy and the broader health sector.
Ms Anne Mustow Company SecretaryGeneral Counsel Jul 2019
-
Peter Mendo Chief Financial Officer
-
Anne Mustow Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 108,369,648 21.99%
Washington H Soul Pattinson And Company Limited 88,670,423 17.99%
Citicorp Nominees Pty Limited 61,387,221 12.46%
J P Morgan Nominees Australia Pty Limited 31,836,056 6.46%
National Nominees Limited 18,272,238 3.70%
Washington H Soul Pattinson&Co Ltd 6,398,049 1.29%
Prudential Nominees Pty Ltd 6,000,000 1.21%
BNP Paribas Noms Pty Ltd 2,996,043 0.60%
BNP Paribas Nominees Pty Ltd 2,895,968 0.58%
J & P Chick Pty Limited 1,850,000 0.37%
Jum Pty Limited 1,567,286 0.31%
Mr Frederick Benjamin Warmbrand 1,345,000 0.27%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 1,248,065 0.25%
Dr Jeffrey Eric Dale Chick & Dr Pamela Hazel Chick 1,200,000 0.24%
Investment Custodial Services Ltd 1,000,000 0.20%
Nulis Nominees (Australia) Limited 906,482 0.18%
Mr Raymond Francis Frew & Mrs Gillian Margaret Frew 820,000 0.16%
Sophia Pty Ltd 736,245 0.14%
Navigator Australia Ltd 730,034 0.14%
EST John Joseph Murphy 681,879 0.13%

Profile

since

Note